Regen BioPharma, Inc. (OTCBB: RGBP) and (PINK: RGBP) announced today the filing of a utility patent application with the United States Patent and Trademark Office covering a novel cancer immunotherapy which induces activation of dendritic cells inside the body in order to stimulate immune-based rejection of cancer. The application builds on Regen's existing expertise in the area of dendritic cells including publications together with scientific advisory board member Dr. Wei-Ping Min (1-3), Professor at the University of Western Ontario, as well as purchase of issued patent # 8,389,708.
"Our filed IND # 16200 for dCellVax leverages dendritic cells that are modified outside of the body to trigger an immune response against breast cancer. In the newly filed patent application we cover means of activating dendritic cells inside the body, with the hope of stimulating T cell responses to clear prostate cancer," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma. "Effectively treating cancer requires a multi-level attack; by leveraging ex vivo activated dendritic cells combined with means of activating dendritic cells in vivo, we anticipate synergistic tumor responses."
Dendritic cells are known as "professional antigen presenting cells", meaning that they activate T cells, which are the effectors of the immune system. By reprogramming the immune system to attack cancer, Regen BioPharma aims to provide a non-toxic and effective means of treating cancer, while sparing patients the side effects of chemotherapy and/or radiation therapy.
"Regen BioPharma is excited about accumulation of intellectual property in its immuno-oncology program. By protecting the inventions of our scientists we aim to not only bring new products to the market, but also to position ourselves for potential licensing and co-development transactions," said David Koos, President, CEO and Chairman of Regen BioPharma, Inc.
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
